EGFR and cancer: Moreover, CDH2 knockdown results in the downregulation of a range of cancer-associated gene signatures (Figures S5B and S5C), including key oncogenic pathways, such as Janus kinase-signal transducer and activator of transcription (JAK-STAT), prolactin, chemokine, and ErbB signaling, as well as the modulation of several genes associated with leukemogenesis and transcription and chromatin remodeling factors (Figures S5C–S5E).